StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report report published on Saturday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
Shares of NASDAQ EVOK traded up $0.03 during mid-day trading on Friday, reaching $0.49. 10,807 shares of the company traded hands, compared to its average volume of 19,751. The company’s fifty day moving average is $0.57 and its two-hundred day moving average is $0.86. Evoke Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $2.40. The stock has a market cap of $4.12 million, a PE ratio of -0.21 and a beta of 0.38.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%. The company had revenue of $1.68 million for the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- Trading Stocks: RSI and Why it’s Useful
- MarketBeat Week in Review – 4/29 – 5/3
- 3 Warren Buffett Stocks to Buy Now
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Why Are Stock Sectors Important to Successful Investing?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
